PCa is treated by ADT, for example, the AR antagonist bicalutamide or enzalutamide, which helps PCa to progress into CRPC, or in the case of AR mutation or suppressed AR expression, the effect of AR to inhibit YAP1 expression is weakened [30]. The gene discussed is AR; the disease is posterior cortical atrophy.